Trial reportEuropean journal of nuclear medicine and molecular imaging2022
Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [
Trial report in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test-retest trial.La Radiologia medica · 2026Trial
- Artificial Intelligence Across the Cancer Theranostics Workflow: Critical Appraisal of Current Evidence and Future Clinical Translation.Molecular imaging and biology · 2026Review
- Deep learning for automatic detection of prostatectomy in CT images of prostate cancer patients.Physical and engineering sciences in medicine · 2026Article
- Emerging frontiers and challenges of artificial intelligence in PSMA-PET imaging: pioneering a new chapter in prostate cancer care.Japanese journal of radiology · 2026Review
- Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels.EJNMMI research · 2026Article
- Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.Abdominal radiology (New York) · 2026Review
- Global research landscape of PSMA-targeted radiopharmaceuticals: a two-decade multidimensional bibliometric analysis.Japanese journal of radiology · 2026Article
- Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).Theranostics · 2026Review
- Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.PloS one · 2026Article
- Deep-learning-based software versus experienced nuclear medicine physician to read [European journal of nuclear medicine and molecular imaging · 2025Article
- Lymph node disease in 2-deoxy-2-fluorodeoxyglucose positron emission tomography/computed tomography imaging: Advances in artificial intelligence-driven automatic segmentation and precise diagnosis.World journal of clinical oncology · 2025Review
- Impact of baselineEuropean journal of nuclear medicine and molecular imaging · 2025Article
- A fully automated AI-based method for tumour detection and quantification on [EJNMMI physics · 2025Article
- PrognosticEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Evaluation of deep learning tools in medical diagnosis and treatment of cancer: research analysis of clinical and randomized clinical trials.Frontiers in network physiology · 2025Review
- An Automated Deep Learning-Based Framework for Uptake Segmentation and Classification on PSMA PET/CT Imaging of Patients with Prostate Cancer.Journal of imaging informatics in medicine · 2024Article
- Automated segmentation of lesions and organs at risk on [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Improving Generalizability of PET DL Algorithms: List-Mode Reconstructions Improve DOTATATE PET Hepatic Lesion Detection Performance.Bioengineering (Basel, Switzerland) · 2024Article
- A Systematic Review on Artificial Intelligence Evaluating Metastatic Prostatic Cancer and Lymph Nodes on PSMA PET Scans.Cancers · 2024Review
- Theranostics and artificial intelligence: new frontiers in personalized medicine.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThe application of automated image analyses could improve and facilitate standardization and consistency of quantification in [
methodsTo evaluate the deep learning algorithm, the automated segmentations of the low-dose CT component of PSMA PET/CT scans from 20 patients were compared to manual segmentations. Dice scores were used to quantify the similarities between the automated and manual segmentations. Next, the automated quantification of tracer uptake in the reference organs and detection and pre-segmentation of potential lesions were evaluated in 339 patients with prostate cancer, who were all enrolled in the phase II/III OSPREY study. Three nuclear medicine physicians performed the retrospective independent reads of OSPREY images with aPROMISE. Quantitative consistency was assessed by the pairwise Pearson correlations and standard deviation between the readers and aPROMISE. The sensitivity of detection and pre-segmentation of potential lesions was evaluated by determining the percent of manually selected abnormal lesions that were automatically detected by aPROMISE.
resultsThe Dice scores for bone segmentations ranged from 0.88 to 0.95. The Dice scores of the PSMA PET/CT reference organs, thoracic aorta and liver, were 0.89 and 0.97, respectively. Dice scores of other visceral organs, including prostate, were observed to be above 0.79. The Pearson correlation for blood pool reference was higher between any manual reader and aPROMISE, than between any pair of manual readers. The standard deviations of reference organ uptake across all patients as determined by aPROMISE (SD = 0.21 blood pool and SD = 1.16 liver) were lower compared to those of the manual readers. Finally, the sensitivity of aPROMISE detection and pre-segmentation was 91.5% for regional lymph nodes, 90.6% for all lymph nodes, and 86.7% for bone in metastatic patients.
conclusionIn this analytical study, we demonstrated the segmentation accuracy of the deep learning algorithm, the consistency in quantitative assessment across multiple readers, and the high sensitivity in detecting potential lesions. The study provides a foundational framework for clinical evaluation of aPROMISE in standardized reporting of PSMA PET/CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.